Millennium Management’s Teva Pharmaceuticals TEVA Stock Holding History

Millennium Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$476K	Sell	15,800 -21,500	-58%	-$692K	﹤0.01%	4796
2025 Q4	$1.16M	Sell	37,300 -534,200	-93%	-$13.2M	﹤0.01%	4384
2025 Q3	$11.5M	Buy	571,500 +472,000	+474%	+$8.29M	﹤0.01%	2241
2025 Q2	$1.67M	Sell	99,500 -60,400	-38%	-$975K	﹤0.01%	4031
2025 Q1	$2.46M	Sell	159,900 -41,800	-21%	-$747K	﹤0.01%	3585
2024 Q4	$4.45M	Buy	201,700 +176,300	+694%	+$3.21M	﹤0.01%	2921
2024 Q3	$458K	Sell	25,400 -23,300	-48%	-$408K	﹤0.01%	4902
2024 Q2	$791K	Sell	48,700 -209,400	-81%	-$3.23M	﹤0.01%	4271
2024 Q1	$3.64M	Sell	258,100 -639,300	-71%	-$8.06M	﹤0.01%	3198
2023 Q4	$9.37M	Buy	897,400 +500,000	+126%	+$4.67M	﹤0.01%	2253
2023 Q3	$4.05M	Sell	397,400 -734,000	-65%	-$6.83M	﹤0.01%	2896
2023 Q2	$8.52M	Buy	1,131,400 +714,200	+171%	+$5.79M	﹤0.01%	2172
2023 Q1	$3.69M	Buy	417,200 +119,100	+40%	+$1.18M	﹤0.01%	2884
2022 Q4	$2.72M	Sell	298,100 -160,100	-35%	-$1.4M	﹤0.01%	3305
2022 Q3	$3.7M	Sell	458,200 -241,800	-35%	-$2.14M	﹤0.01%	3181
2022 Q2	$5.26M	Sell	700,000 -1,600,000	-70%	-$13.9M	﹤0.01%	2754
2022 Q1	$21.6M	Sell	2,300,000 -500,000	-18%	-$4.17M	0.01%	1316
2021 Q4	$22.4M	Buy	2,800,000 +1,600,000	+133%	+$14.4M	0.01%	1329
2021 Q3	$11.7M	Buy	1,200,000 +490,000	+69%	+$4.59M	0.01%	1868
2021 Q2	$7.03M	Sell	710,000 -546,400	-43%	-$5.78M	﹤0.01%	2318
2021 Q1	$14.5M	Buy	+1,256,400	New	+$14.4M	0.01%	1400
2020 Q1	–	Sell	-1,300,000	Closed	-$12.7M	–	4464
2019 Q4	$12.7M	Sell	1,300,000 -1,757,500	-57%	-$15.7M	0.02%	1175
2019 Q3	$21M	Buy	+3,057,500	New	+$23.4M	0.03%	744
2017 Q1	–	Sell	-650,000	Closed	-$23.6M	–	3830
2016 Q4	$23.6M	Buy	+650,000	New	+$26M	0.05%	534
2014 Q1	–	Sell	-47,400	Closed	-$1.9M	–	3871
2013 Q4	$1.9M	Sell	47,400 -9,900	-17%	-$390K	0.01%	1868
2013 Q3	$2.17M	Sell	57,300 -15,300	-21%	-$597K	0.01%	1639
2013 Q2	$2.85M	Buy	+72,600	New	+$2.83M	0.01%	1370

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's TEVA Position: Q1 2026 in Review

Millennium Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 1,893,845 shares worth $57M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Millennium Management previously reported a position in TEVA as recently as Q3 2025.

Millennium Management first reported a position in TEVA in Q2 2013 and has held it in 51 quarters since. The position peaked at $560M in Q1 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Millennium Management held 1,893,845 shares of Teva Pharmaceuticals worth $57M as of Q1 2026.
Teva Pharmaceuticals was a new Millennium Management position in Q1 2026.
Teva Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #753 holding.
Millennium Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Millennium Management's Teva Pharmaceuticals position peaked at $560M in Q1 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.